Sikiric P, Seiwerth S, Aralica G, et al
a growth hormone-releasing factor analog, is FDA-approved for the treatment of HIV-associated lipodystrophy , with studies showing significant reduction in visceral adipose tissue (VAT) after 26 weeks of useSource: Falutz et al., New England Journal of Medicine, 2010
About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features NFL Sunday Ticket 2026 Google LLC Luxxewhite - YouTube
Some research suggests that intermittent dosing protocols or cycling strategies may help keep receptor response during extended research periods
Archived from the original on April 10, 2024
176-180 Use of atomoxetine avoids some of the complications associated with stimulants, notably tics and sleep disturbances, but there is an increased risk of suicidal thinking in children and adolescents given the drug, so people in these age groups should be carefully monitored for the first few months after beginning treatment or changing dosage
